Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Biliary Tract Diseases

Free Subscription Articles published in Gut Retrieve available abstracts of 75 articles: HTML format

Single Articles

April 2026
1. MENG XL, Lu JC, Zhang YX, Pu P, et al
   Norepinephrine promotes tumour cell aggressiveness and NK cell ferroptosis via ADRB2 in intrahepatic cholangiocarcinoma with perineural invasion.
   Gut. 2026 Apr 20:gutjnl-2025-337595. doi: 10.1136/gutjnl-2025-337595.
   PubMed     Abstract available
   
   
   March 2026
2. AWONIYI M, El Hag M, Hernandez J, Yang Q, et al
   Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model.
   Gut. 2026 Mar 23:gutjnl-2025-336675. doi: 10.1136/gutjnl-2025-336675.
   PubMed     Abstract available
   
   
   
3. GEHL V, O'Rourke CJ, Cornillet M, Nousias O, et al
   Molecular and cellular consequences of tumour-autonomous IL-6 signalling in intrahepatic cholangiocarcinoma.
   Gut. 2026 Mar 19:gutjnl-2025-337579. doi: 10.1136/gutjnl-2025-337579.
   PubMed     Abstract available
   
   
   February 2026
4. ROMEO M, Dallio M, Di Nardo F, Napolitano C, et al
   Beyond gastrointestinal symptom burden: exploring the impact of previous cholecystectomy on ultrasound-based hepatocellular carcinoma surveillance in patients with liver cirrhosis.
   Gut. 2026 Feb 3:gutjnl-2026-338023. doi: 10.1136/gutjnl-2026-338023.
   PubMed    
   
   
   
5. CHEN L, Li P, Park MJ, Chen Z, et al
   CPS1: a multipurpose mitochondrial enzyme, bile protein, acute liver injury biomarker, and cytokine.
   Gut. 2026 Feb 2:gutjnl-2024-333082. doi: 10.1136/gutjnl-2024-333082.
   PubMed     Abstract available
   
   
   January 2026
6. VIJAY-KUMAR M, Yeoh BS, Gewirtz AT
   Hydroxylation matters! Microbial bile acid metabolism and colorectal cancer.
   Gut. 2026 Jan 28:gutjnl-2025-337583. doi: 10.1136/gutjnl-2025-337583.
   PubMed    
   
   
   
7. SUKUBO NG, Caime C, Gerussi A, Invernizzi P, et al
   Kupffer cell autophagy emerges as a central regulator of immune dysregulation in primary biliary cholangitis.
   Gut. 2026 Jan 27:gutjnl-2025-337652. doi: 10.1136/gutjnl-2025-337652.
   PubMed    
   
   
   
8. WEBSTER GJ BSC MD FRCP
   Commentary on: gutjnl-2025-335548.R2-endoscopic retrograde cholangiopancreatography (ERCP) services across the UK.
   Gut. 2026 Jan 6:gutjnl-2025-337099. doi: 10.1136/gutjnl-2025-337099.
   PubMed    
   
   
   December 2025
9. OSSWALD A, Wortmann E, Wylensek D, Kuhls S, et al
   Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer.
   Gut. 2025 Dec 18:gutjnl-2024-332243. doi: 10.1136/gutjnl-2024-332243.
   PubMed     Abstract available
   
   
   
10. LUO PY, Ma M, Liu MC, Wu YH, et al
    Autophagy of Kupffer cells modulates CD8(+) T cell activation in primary biliary cholangitis.
    Gut. 2025 Dec 10:gutjnl-2025-335611. doi: 10.1136/gutjnl-2025-335611.
    PubMed     Abstract available
    
    
    
11. CORRALES F, Cardinale V
    Multiomics- and artificial intelligence-powered research platforms for enhancing understanding and prediction of the cholangiocarcinoma patient journey.
    Gut. 2025 Dec 4:gutjnl-2025-337219. doi: 10.1136/gutjnl-2025-337219.
    PubMed    
    
    
    
12. ZHOU H, Li H, Wu N, Calvisi DF, et al
    SIRT6-GLUL axis: rewiring nitrogen metabolism in intrahepatic cholangiocarcinoma.
    Gut. 2025 Dec 3:gutjnl-2025-337554. doi: 10.1136/gutjnl-2025-337554.
    PubMed    
    
    
    October 2025
13. WANG S, Guo Z, Sun B, Liu K, et al
    Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer.
    Gut. 2025 Oct 28:gutjnl-2025-335513. doi: 10.1136/gutjnl-2025-335513.
    PubMed     Abstract available
    
    
    
14. ZHANG M, Chen C, Zhang H, Long T, et al
    SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL.
    Gut. 2025 Oct 23:gutjnl-2025-335729. doi: 10.1136/gutjnl-2025-335729.
    PubMed     Abstract available
    
    
    
15. RUILOVA SOSORANGA E, Tack J
    Insulin-like peptide 5: a new key player in IBS with diarrhoea and bile acid malabsorption?
    Gut. 2025 Oct 17:gutjnl-2025-336390. doi: 10.1136/gutjnl-2025-336390.
    PubMed    
    
    
    
16. 
    Correction: Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer.
    Gut. 2025;74:e21.
    PubMed    
    
    
    
17. SIRTL S, Zorniak M, Mayerle J
    Response to 'Biliary sludge and microlithiasis: are we covering the full spectrum of lithogenic biliary disorders?'.
    Gut. 2025 Oct 5:gutjnl-2025-337089. doi: 10.1136/gutjnl-2025-337089.
    PubMed    
    
    
    September 2025
18. SHEN Y, Jin X, Song W, Fang T, et al
    Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies.
    Gut. 2025 Sep 29:gutjnl-2025-335904. doi: 10.1136/gutjnl-2025-335904.
    PubMed     Abstract available
    
    
    
19. LOZANO E, Vaquero J
    Aurora kinase B at the nexus of cholesterol metabolism and therapy response in cholangiocarcinoma.
    Gut. 2025 Sep 27:gutjnl-2025-336445. doi: 10.1136/gutjnl-2025-336445.
    PubMed    
    
    
    
20. MENDONCA PROENCA I, Lera Dos Santos ME, Maluf-Filho F
    Biliary sludge and microlithiasis: are we covering the full spectrum of lithogenic biliary disorders?
    Gut. 2025 Sep 19:gutjnl-2025-336609. doi: 10.1136/gutjnl-2025-336609.
    PubMed    
    
    
    
21. AHMED W, Haworth E, Sharp L, Dobson C, et al
    Endoscopic Retrograde Cholangiopancreatography (ERCP) services across the UK.
    Gut. 2025 Sep 10:gutjnl-2025-335548. doi: 10.1136/gutjnl-2025-335548.
    PubMed    
    
    
    August 2025
22. MILARDI G, Franceschini B, Camisaschi C, Puccio S, et al
    Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome.
    Gut. 2025 Aug 31:gutjnl-2025-334861. doi: 10.1136/gutjnl-2025-334861.
    PubMed     Abstract available
    
    
    
23. KONINGS B, Balsiger LM, Hreinsson JP, Simren M, et al
    Global prevalence and gastrointestinal symptom burden of individuals with a history of cholecystectomy.
    Gut. 2025 Aug 12:gutjnl-2024-334531. doi: 10.1136/gutjnl-2024-334531.
    PubMed     Abstract available
    
    
    
24. MERCADO-GOMEZ M, Goikoetxea-Usandizaga N, Gine AE, Merlos Rodrigo MA, et al
    Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential.
    Gut. 2025 Aug 5:gutjnl-2024-333255. doi: 10.1136/gutjnl-2024-333255.
    PubMed     Abstract available
    
    
    
25. VILLA E
    CNNM4: a ferroptotic vulnerability in cholangiocarcinoma.
    Gut. 2025 Aug 5:gutjnl-2025-335061. doi: 10.1136/gutjnl-2025-335061.
    PubMed    
    
    
    July 2025
26. LIU F, Chen W, Zhang Z, Zeng W, et al
    Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma.
    Gut. 2025 Jul 31:gutjnl-2025-335291. doi: 10.1136/gutjnl-2025-335291.
    PubMed     Abstract available
    
    
    
27. BANNON CA, Walters JRF, Wu T, Kay RG, et al
    Insulin-like peptide 5 is released in response to bile acid in the rectum and is associated with diarrhoea severity in patients with bile acid diarrhoea.
    Gut. 2025 Jul 23:gutjnl-2025-335393. doi: 10.1136/gutjnl-2025-335393.
    PubMed     Abstract available
    
    
    
28. MORALI K, Vicent S
    To be or not to be (a biliary cancer): RAS (signalling) is the question.
    Gut. 2025 Jul 15:gutjnl-2025-335690. doi: 10.1136/gutjnl-2025-335690.
    PubMed    
    
    
    June 2025
29. LOU C, Lan T, Xu S, Hu X, et al
    Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility.
    Gut. 2025 Jun 9:gutjnl-2025-334763. doi: 10.1136/gutjnl-2025-334763.
    PubMed     Abstract available
    
    
    
30. ZHU C, Boucheron N, Al-Rubaye O, Chung BK, et al
    24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T(H)17 pathogenicity and transdifferentiation.
    Gut. 2025;74:1079-1093.
    PubMed     Abstract available
    
    
    
31. ZHANG W, Tao L, Wang F, Shao B, et al
    Endoscopic mucosal resection in the pancreatobiliary system under direct cholangiopancreatoscopic guidance.
    Gut. 2025 Jun 6:gutjnl-2025-335707. doi: 10.1136/gutjnl-2025-335707.
    PubMed    
    
    
    May 2025
32. LI P, Lei Q, Yu X, Shen Y, et al
    Commensal Bacteroides T6SS alleviate GI-aGVHD via mediating gut microbiota composition and bile acids metabolism.
    Gut. 2025 May 28:gutjnl-2024-334565. doi: 10.1136/gutjnl-2024-334565.
    PubMed     Abstract available
    
    
    
33. ROSNER T, Rupp C, Lechler C, Bauer U, et al
    Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer.
    Gut. 2025 May 12:gutjnl-2024-333238. doi: 10.1136/gutjnl-2024-333238.
    PubMed     Abstract available
    
    
    
34. HE Y, Kostallari E
    When getting reactive becomes the nORM: the emerging roles of proinflammatory cholangiokines.
    Gut. 2025 May 7:gutjnl-2025-335426. doi: 10.1136/gutjnl-2025-335426.
    PubMed    
    
    
    April 2025
35. LIU H, Yin G, Franco Leonardi B, Lan T, et al
    Reactive cholangiocyte-derived ORM2 drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming.
    Gut. 2025 Apr 8:gutjnl-2024-334425. doi: 10.1136/gutjnl-2024-334425.
    PubMed     Abstract available
    
    
    
36. ZHURAVLEVA E, Lewinska M, O'Rourke CJ, Pea A, et al
    Mutational signatures define immune and Wnt-associated subtypes of ampullary carcinoma.
    Gut. 2025;74:804-814.
    PubMed     Abstract available
    
    
    March 2025
37. TAN L, Wu WKK
    24-Nor-ursodeoxycholic acid: a novel treatment targeting T-cell-mediated immune dysregulation in primary sclerosing cholangitis and beyond.
    Gut. 2025 Mar 26:gutjnl-2025-334966. doi: 10.1136/gutjnl-2025-334966.
    PubMed    
    
    
    February 2025
38. BANG JY, Faraj Agha M, Hawes R, Varadarajulu S, et al
    Rate of suitable cases for primary EUS-guided biliary drainage in distal malignant biliary obstruction.
    Gut. 2025 Feb 26:gutjnl-2025-334979. doi: 10.1136/gutjnl-2025-334979.
    PubMed    
    
    
    December 2024
39. LIM Y, Kang S, Shah A, Holtmann G, et al
    Is the biogeography of the mucosa-associated microbiota a key factor affecting primary sclerosing cholangitis disease course and treatment?
    Gut. 2024 Dec 20:gutjnl-2024-334069. doi: 10.1136/gutjnl-2024-334069.
    PubMed    
    
    
    
40. HOLLENBACH M, Heise C, Abou-Ali E, Gulla A, et al
    Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis.
    Gut. 2024 Dec 12:gutjnl-2022-327996. doi: 10.1136/gutjnl-2022-327996.
    PubMed     Abstract available
    
    
    
41. DESERT R, Goyal L, Baumert TF
    Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment.
    Gut. 2024 Dec 6:gutjnl-2024-333632. doi: 10.1136/gutjnl-2024-333632.
    PubMed    
    
    
    October 2024
42. ONNEKINK AM, Gorris M, Bekkali NL, Bos P, et al
    Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial.
    Gut. 2024 Oct 10:gutjnl-2024-332695. doi: 10.1136/gutjnl-2024-332695.
    PubMed     Abstract available
    
    
    September 2024
43. ELURBIDE J, Colyn L, Latasa MU, Uriarte I, et al
    Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.
    Gut. 2024 Sep 11:gutjnl-2024-332998. doi: 10.1136/gutjnl-2024-332998.
    PubMed     Abstract available
    
    
    
44. COTE GA, Elmunzer BJ, Nitchie H, Kwon RS, et al
    Sphincterotomy for biliary sphincter of Oddi disorder and idiopathic acute recurrent pancreatitis: the RESPOnD longitudinal cohort.
    Gut. 2024 Sep 7:gutjnl-2024-332686. doi: 10.1136/gutjnl-2024-332686.
    PubMed     Abstract available
    
    
    August 2024
45. SHI C, Hong J, Bai B, Li S, et al
    Morphological consistency between EUS and ERCP in diagnosing biliary sludge and microlithiasis.
    Gut. 2024 Aug 22:gutjnl-2024-332971. doi: 10.1136/gutjnl-2024-332971.
    PubMed    
    
    
    
46. KHAN SA, Rushbrook SM, Kendall TJ, Zen Y, et al
    Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
    Gut. 2024 Aug 19:gutjnl-2024-333359. doi: 10.1136/gutjnl-2024-333359.
    PubMed    
    
    
    July 2024
47. HOV JR
    Sclerosing cholangitis and inflammatory bowel disease: a paradoxical relationship?
    Gut. 2024 Jul 17:gutjnl-2024-332835. doi: 10.1136/gutjnl-2024-332835.
    PubMed    
    
    
    June 2024
48. KEGGENHOFF FL, Castven D, Becker D, Stojkovic S, et al
    PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.
    Gut. 2024 Jun 10:gutjnl-2023-331237. doi: 10.1136/gutjnl-2023-331237.
    PubMed     Abstract available
    
    
    
49. BEDKE T, Stumme F, Tomczak M, Steglich B, et al
    Protective function of sclerosing cholangitis on IBD.
    Gut. 2024 Jun 5:gutjnl-2023-330856. doi: 10.1136/gutjnl-2023-330856.
    PubMed     Abstract available
    
    
    May 2024
50. HE H, Chen S, Yu Y, Fan Z, et al
    Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer.
    Gut. 2024 May 6:gutjnl-2023-331773. doi: 10.1136/gutjnl-2023-331773.
    PubMed     Abstract available
    
    
    April 2024
51. 
    Correction: Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
    Gut. 2024 Apr 23:gutjnl-2016-312278corr1. doi: 10.1136/gutjnl-2016-312278.
    PubMed    
    
    
    
52. FABRIS L, Pol J
    Mast cells and histamine in cholangiocarcinoma: exploring overlooked avenues for enhanced patient management.
    Gut. 2024 Apr 18:gutjnl-2024-332288. doi: 10.1136/gutjnl-2024-332288.
    PubMed    
    
    
    
53. BANG JY, Arnoletti JP, Wagner A, Varadarajulu S, et al
    EUS-guided gallbladder drainage in acute cholecystitis: response to letter to the editor.
    Gut. 2024 Apr 12:gutjnl-2024-332342. doi: 10.1136/gutjnl-2024-332342.
    PubMed    
    
    
    March 2024
54. HAYLER R, Tuft C, Fisher O
    Head of pancreas mass with biliary obstruction: an unusual cause.
    Gut. 2024 Mar 22:gutjnl-2024-332268. doi: 10.1136/gutjnl-2024-332268.
    PubMed    
    
    
    
55. LARGHI A, van Wanrooij RLJ, Bronswijk M, Vanella G, et al
    Cholecystectomy following EUS-guided gallbladder drainage in patients with acute cholecystitis at high surgical risk: friend or foe?
    Gut. 2024 Mar 22:gutjnl-2024-332273. doi: 10.1136/gutjnl-2024-332273.
    PubMed    
    
    
    
56. SHI A, Liu Z, Fan Z, Li K, et al
    Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment.
    Gut. 2024 Mar 8:gutjnl-2023-331715. doi: 10.1136/gutjnl-2023-331715.
    PubMed     Abstract available
    
    
    January 2024
57. TOTH R, Brindley PJ, Vaquero J
    Enhancing the opportunities for cholangiocarcinoma precision therapy.
    Gut. 2024 Jan 16:gutjnl-2023-331480. doi: 10.1136/gutjnl-2023-331480.
    PubMed    
    
    
    December 2023
58. HANNEMANN A, Mayerle J, Beyer G
    Response to: Correspondence on 'Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion' by Wang et al.
    Gut. 2023 Dec 2:gutjnl-2023-331525. doi: 10.1136/gutjnl-2023-331525.
    PubMed    
    
    
    November 2023
59. BANG JY, Arnoletti JP, Wagner A, Varadarajulu S, et al
    EUS-guided gallbladder drainage in acute cholecystitis: long-term problems with surgical approach.
    Gut. 2023 Nov 24:gutjnl-2023-331245. doi: 10.1136/gutjnl-2023-331245.
    PubMed    
    
    
    
60. HONG JH, Yong CH, Heng HL, Chan JY, et al
    Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.
    Gut. 2023 Nov 24:gutjnl-2023-330483. doi: 10.1136/gutjnl-2023-330483.
    PubMed     Abstract available
    
    
    
61. FRITZSCHE JA, Smit E, Ponsioen CY, Voermans RP, et al
    Time to focus on the real potential benefit of endobiliary radiofrequency ablation: stent patency in patients with cholangiocarcinoma.
    Gut. 2023 Nov 21:gutjnl-2023-331359. doi: 10.1136/gutjnl-2023-331359.
    PubMed    
    
    
    
62. CHEN L, Qiu W, Sun X, Gao M, et al
    Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis.
    Gut. 2023 Nov 9:gutjnl-2023-330784. doi: 10.1136/gutjnl-2023-330784.
    PubMed     Abstract available
    
    
    
63. NAKAGAMI S, Morita T, Yazumi S
    Rare cause of obstructive jaundice.
    Gut. 2023 Nov 6:gutjnl-2023-330496. doi: 10.1136/gutjnl-2023-330496.
    PubMed    
    
    
    October 2023
64. ARECHEDERRA M, Casadei Gardini A, Raggi C
    More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma.
    Gut. 2023 Oct 27:gutjnl-2023-331119. doi: 10.1136/gutjnl-2023-331119.
    PubMed    
    
    
    
65. WANG F, Peng L, Liu Y
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion.
    Gut. 2023 Oct 10:gutjnl-2023-331163. doi: 10.1136/gutjnl-2023-331163.
    PubMed    
    
    
    
66. LI JS, Fang J, Li ZS
    Endoluminal radiofrequency ablation prior to stenting for malignant biliary obstruction: really time to say goodbye?
    Gut. 2023 Oct 5:gutjnl-2023-331070. doi: 10.1136/gutjnl-2023-331070.
    PubMed    
    
    
    
67. ZECHER BF, Ellinghaus D, Schloer S, Niehrs A, et al
    HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells.
    Gut. 2023 Oct 3:gutjnl-2023-329524. doi: 10.1136/gutjnl-2023-329524.
    PubMed     Abstract available
    
    
    September 2023
68. RUSHBROOK SM, Kendall TJ, Zen Y, Albazaz R, et al
    British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
    Gut. 2023 Sep 28:gutjnl-2023-330029. doi: 10.1136/gutjnl-2023-330029.
    PubMed     Abstract available
    
    
    
69. O'ROURKE CJ, Salati M, Rae C, Carpino G, et al
    Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
    Gut. 2023 Sep 27:gutjnl-2023-330748. doi: 10.1136/gutjnl-2023-330748.
    PubMed     Abstract available
    
    
    August 2023
70. JAROSOVA J, Zarivnijova L, Cibulkova I, Mares J, et al
    Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial.
    Gut. 2023 Aug 31:gutjnl-2023-329700. doi: 10.1136/gutjnl-2023-329700.
    PubMed     Abstract available
    
    
    July 2023
71. HE X, Gao N, Lv F, Wu F, et al
    Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
    Gut. 2023 Jul 24:gutjnl-2023-330271. doi: 10.1136/gutjnl-2023-330271.
    PubMed    
    
    
    April 2023
72. LEWINSKA M, Karhus ML, Ellegaard AG, Romero-Gomez M, et al
    Serum lipidome unravels a diagnostic potential in bile acid diarrhoea.
    Gut. 2023 Apr 18:gutjnl-2022-329213. doi: 10.1136/gutjnl-2022-329213.
    PubMed     Abstract available
    
    
    
73. ZORNIAK M, Sirtl S, Beyer G, Mahajan UM, et al
    Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis.
    Gut. 2023 Apr 18:gutjnl-2022-327955. doi: 10.1136/gutjnl-2022-327955.
    PubMed     Abstract available
    
    
    February 2023
74. HALLENSLEBEN ND, Stassen PMC, Schepers NJ, Besselink MG, et al
    Patient selection for urgent endoscopic retrograde cholangio-pancreatography by endoscopic ultrasound in predicted severe acute biliary pancreatitis (APEC-2): a multicentre prospective study.
    Gut. 2023 Feb 27:gutjnl-2022-328258. doi: 10.1136/gutjnl-2022-328258.
    PubMed     Abstract available
    
    
    
75. BEYER G, Kasprowicz F, Hannemann A, Aghdassi A, et al
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: a population-based, cross-sectional cohort study.
    Gut. 2023 Feb 24:gutjnl-2021-326106. doi: 10.1136/gutjnl-2021-326106.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum